<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461942</url>
  </required_header>
  <id_info>
    <org_study_id>2004BA702B02-2</org_study_id>
    <nct_id>NCT00461942</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Neuroprotection Effect of Green Tea Polyphenol in De Novo Parkinson's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Green Tea Polyphenol, an extraction from
      Green Tea is effective and safe in the treatment of De Novo Parkinson's disease Patients
      without taking any antiparkinsonism drug
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary outcome measurement is UPDRS using a delay start design. Total 480 de novo PD
      patients divided into three dosage groups of green tea polyphenol and one placebo control
      group. Patients will be treated for one year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delay of progression of Motor dysfunction</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood;</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Daily life</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Green Tea Polyphenols (EGCG/ECG)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give informed consent

          -  Age 30 years or older at time of diagnosis of Parkinson's disease

          -  Diagnosed as having typical PD

          -  Parkinson's disease duration of no more than 5 years

          -  No current dopaminergic or other forms of anti-parkinsonism therapy

          -  Hoehn and Yahr stage &lt; 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piu Chan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Institute of Geriatrics, Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>August 15, 2011</last_update_submitted>
  <last_update_submitted_qc>August 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2011</last_update_posted>
  <keyword>Health Food;</keyword>
  <keyword>Green Tea;</keyword>
  <keyword>Neuroprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

